Home > Insider Trading > Filing (0000899243-21-026780)

Filing Details

Accession Number:: 0000899243-21-026780
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-30 18:00:34
Reporting Period:: 2021-06-28

Accepted Time:: 2021-06-30 18:00:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1745999	Beam Therapeutics Inc.	BEAM	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1786322	Giuseppe Ciaramella	C/O Beam Therapeutics Inc., 26 Landsdowne Street Cambridge MA 02139	President & Cso	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-06-28	78,580	$17.00	123,341	No	4	M	Direct
Common Stock	Disposition	2021-06-28	2,405	$103.83	120,936	No	4	S	Direct
Common Stock	Disposition	2021-06-28	5,464	$104.40	115,472	No	4	S	Direct
Common Stock	Disposition	2021-06-28	7,040	$105.52	108,432	No	4	S	Direct
Common Stock	Disposition	2021-06-28	10,444	$106.35	97,988	No	4	S	Direct
Common Stock	Disposition	2021-06-28	10,829	$107.30	87,159	No	4	S	Direct
Common Stock	Disposition	2021-06-28	30,369	$108.11	56,790	No	4	S	Direct
Common Stock	Disposition	2021-06-28	9,856	$109.32	46,934	No	4	S	Direct
Common Stock	Disposition	2021-06-28	2,173	$110.00	44,761	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-06-28	78,580	$0.00	78,580	$17.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
432,313		2030-02-05	No	4	M	Direct

Footnotes

The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.74 to $103.97, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.04 to $104.96, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.01 to $105.98, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.00 to $106.97, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.99, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.00 to $108.90, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.00 to $109.95, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.01, inclusive.
25% of the shares subject to the stock option shall vest on the first anniversary of the vesting commencement date, February 5, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.